STADA Arzneimittel to acquire the pharmaceuticals unit of Horizon Capital-backed Biopharma.

STADA Arzneimittel, a global manufacturer of generic drugs and consumer healthcare products, agreed to acquire the pharmaceuticals unit of Horizon Capital-backed Biopharma, a Ukrainian pharmaceutical company. Financial terms were not disclosed. “STADA’s acquisition of the pharmaceutical business of Biopharma is a logical step within STADA’s European growth strategy. We will integrate Ukraine as soon as possible into our European organization,” Steffen Wagner, STADA Head of European Markets.